Bangalore (Karnataka) [India], May 21: A first-of-its-kind clinical trial in India shows remarkable results for people with diabetes. The trial was conducted using BugSpeaks, a flagship technology of Leucine Rich Bio, India's first microbiome-based company. BugSpeaks is a gut microbiome prof
Machine learning techniques can predict with certainty the likelihood that patients with type 2 diabetes would have poor glycemic control. The length of type 2 diabetes, previous glucose levels, and the patient's use of anti-diabetic medications are the most crucial variables influencing gly